JP2011526792A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526792A5 JP2011526792A5 JP2011516886A JP2011516886A JP2011526792A5 JP 2011526792 A5 JP2011526792 A5 JP 2011526792A5 JP 2011516886 A JP2011516886 A JP 2011516886A JP 2011516886 A JP2011516886 A JP 2011516886A JP 2011526792 A5 JP2011526792 A5 JP 2011526792A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- domain
- multispecific fusion
- antagonist
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000037865 fusion proteins Human genes 0.000 claims description 34
- 108020001507 fusion proteins Proteins 0.000 claims description 34
- 239000005557 antagonist Substances 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 108010028006 B-Cell Activating Factor Proteins 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 2
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims description 2
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 2
- 102000003814 Interleukin-10 Human genes 0.000 claims description 2
- 108090000174 Interleukin-10 Proteins 0.000 claims description 2
- 102100033461 Interleukin-17A Human genes 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 229940124044 RANKL antagonist Drugs 0.000 claims description 2
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 7
- 230000009870 specific binding Effects 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13409708P | 2008-07-02 | 2008-07-02 | |
| US13409508P | 2008-07-02 | 2008-07-02 | |
| US13410108P | 2008-07-02 | 2008-07-02 | |
| US13410008P | 2008-07-02 | 2008-07-02 | |
| US13409908P | 2008-07-02 | 2008-07-02 | |
| US13409608P | 2008-07-02 | 2008-07-02 | |
| US13409808P | 2008-07-02 | 2008-07-02 | |
| US61/134,095 | 2008-07-02 | ||
| US61/134,098 | 2008-07-02 | ||
| US61/134,099 | 2008-07-02 | ||
| US61/134,100 | 2008-07-02 | ||
| US61/134,101 | 2008-07-02 | ||
| US61/134,096 | 2008-07-02 | ||
| US61/134,097 | 2008-07-02 | ||
| US18009709P | 2009-05-20 | 2009-05-20 | |
| US61/180,097 | 2009-05-20 | ||
| PCT/US2009/049603 WO2010003108A2 (en) | 2008-07-02 | 2009-07-02 | TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011526792A JP2011526792A (ja) | 2011-10-20 |
| JP2011526792A5 true JP2011526792A5 (https=) | 2012-08-16 |
Family
ID=41051379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516886A Pending JP2011526792A (ja) | 2008-07-02 | 2009-07-02 | ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110152173A1 (https=) |
| EP (1) | EP2310410A2 (https=) |
| JP (1) | JP2011526792A (https=) |
| KR (1) | KR20110044991A (https=) |
| CN (1) | CN102171247A (https=) |
| AU (1) | AU2009266863A1 (https=) |
| BR (1) | BRPI0914005A2 (https=) |
| CA (1) | CA2729749A1 (https=) |
| EA (1) | EA201170028A1 (https=) |
| IL (1) | IL210264A0 (https=) |
| MX (1) | MX2011000041A (https=) |
| NZ (1) | NZ590668A (https=) |
| WO (1) | WO2010003108A2 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2519227C (en) | 2003-03-19 | 2013-12-03 | Biogen Idec Ma Inc. | Nogo receptor binding protein |
| US8486893B2 (en) | 2004-06-24 | 2013-07-16 | Biogen Idec Ma Inc. | Treatment of conditions involving demyelination |
| HRP20131066T1 (hr) | 2005-07-08 | 2013-12-06 | Biogen Idec Ma Inc. | Sp35 antitijela i njihova upotreba |
| PE20081216A1 (es) | 2006-09-01 | 2008-09-04 | Therapeutic Human Polyclonals Inc | Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos |
| MX2011000071A (es) * | 2008-07-02 | 2011-05-03 | Emergent Product Dev Seattle | Inmunoterapeuticos de interleucina-6 (il6). |
| CA2729961C (en) * | 2008-07-09 | 2018-05-01 | Biogen Idec Ma Inc. | Li113, li62 variant co2, anti-lingo antibodies |
| AU2009303318B2 (en) * | 2008-10-10 | 2016-06-30 | Aptevo Research And Development Llc | TCR complex immunotherapeutics |
| WO2011079308A2 (en) * | 2009-12-23 | 2011-06-30 | Emergent Product Development Seattle, Llc | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
| KR101004363B1 (ko) | 2010-03-19 | 2010-12-28 | 가톨릭대학교 산학협력단 | 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＩＬ－２１ 이중 길항제 |
| KR101004362B1 (ko) | 2010-03-19 | 2010-12-28 | 가톨릭대학교 산학협력단 | 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제 |
| KR101712874B1 (ko) * | 2010-09-30 | 2017-03-07 | 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 | 인간화 항 TNF α 항체 및 그의 항원 결합 단편 (Fab) 및 용도 |
| PT2673373T (pt) * | 2011-02-08 | 2018-12-05 | Medimmune Llc | Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização |
| WO2013065343A1 (ja) * | 2011-10-31 | 2013-05-10 | 株式会社 島津製作所 | 非ペプチドヒンジ部含有フレキシブル抗体様分子 |
| WO2013075027A2 (en) * | 2011-11-17 | 2013-05-23 | Emergent Product Development Seattle, Llc | Anti-sil6xr complex binding domains and methods of use |
| HK1202587A1 (en) | 2011-12-15 | 2015-10-02 | The Royal Institution For The Advancement Of Learning/Mcgill University | Soluble igf receptor fc fusion proteins and uses thereof |
| EP2809660B1 (en) | 2012-02-02 | 2016-01-20 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| WO2013150043A1 (en) | 2012-04-05 | 2013-10-10 | F. Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
| JP6509724B2 (ja) | 2012-04-20 | 2019-05-08 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Ｃｄ３結合ポリペプチド |
| AU2013259276B2 (en) | 2012-05-10 | 2018-03-22 | Bioatla Llc | Multi-specific monoclonal antibodies |
| KR102142161B1 (ko) | 2012-05-14 | 2020-08-06 | 바이오젠 엠에이 인코포레이티드 | 운동 뉴런 관련 병태 치료용 lingo-2 길항제 |
| CN103060274B (zh) * | 2012-12-28 | 2013-12-11 | 首都医科大学 | Rankl-tnf样区鼠源性单克隆抗体及其制备方法与应用 |
| EP2938634A2 (en) * | 2012-12-28 | 2015-11-04 | AbbVie Inc. | Dual specific binding proteins having a receptor sequence |
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| US9416197B2 (en) | 2013-11-01 | 2016-08-16 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease |
| JP2018504400A (ja) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用 |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| US11254744B2 (en) | 2015-08-07 | 2022-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| SG11201802698XA (en) * | 2015-10-29 | 2018-05-30 | Hoffmann La Roche | Transgenic rabbit with common light chain |
| EP3293293A1 (en) * | 2016-09-08 | 2018-03-14 | Italfarmaco SpA | Hc-cdr3-only libraries with reduced combinatorial redundancy and optimized loop length distribution |
| US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
| MY201312A (en) | 2017-06-02 | 2024-02-16 | Pfizer | Antibodies specific for flt3 and their uses |
| JP6895165B2 (ja) * | 2017-06-06 | 2021-06-30 | 知和 松浦 | α１−アンチキモトリプシンを含むバイオマーカー |
| EP3655439A1 (en) | 2017-07-20 | 2020-05-27 | Aptevo Research and Development LLC | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
| WO2019241216A1 (en) | 2018-06-14 | 2019-12-19 | Bioatla, Llc | Multi-specific antibody constructs |
| CA3102641A1 (en) * | 2018-06-22 | 2019-12-26 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
| JP7525471B2 (ja) | 2018-07-24 | 2024-07-30 | メディミューン，エルエルシー | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
| BR112021006622A2 (pt) | 2018-10-09 | 2021-07-20 | Medimmune, Llc | combinações de anticorpos anti-staphylococcus aureus |
| KR102404684B1 (ko) * | 2019-01-15 | 2022-06-07 | 서울대학교산학협력단 | 인슐린 유사 성장인자 2 억제제를 포함하는 만성 폐질환의 예방 또는 치료용 조성물 |
| US20220242962A1 (en) | 2019-08-12 | 2022-08-04 | Aptevo Research And Development Llc | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40 |
| WO2021146328A1 (en) | 2020-01-13 | 2021-07-22 | Aptevo Research And Development Llc | Formulations for protein therapeutics |
| KR20230118573A (ko) * | 2020-11-11 | 2023-08-11 | 에이치큐 한 | 액티빈/tgf-베타 및 rankl의 이작용성 길항제 및 이의 용도 |
| CN112451670B (zh) * | 2020-11-25 | 2024-01-02 | 沣潮医药科技（上海）有限公司 | 异位内膜治疗的组合物和预后检测试剂盒 |
| IL303328A (en) | 2020-12-01 | 2023-07-01 | Aptevo Res & Development Llc | Heterodimeric psma and cd3-binding bispecific antibodies |
| CN115073607A (zh) * | 2021-03-12 | 2022-09-20 | 上海康岱生物医药技术股份有限公司 | Tnfr2与baff受体的融合蛋白 |
| EP4341291A1 (en) | 2021-05-21 | 2024-03-27 | Aptevo Research and Development LLC | Dosing regimens for protein therapeutics |
| WO2023164898A1 (zh) * | 2022-03-03 | 2023-09-07 | 上海赛金生物医药有限公司 | 一种重组融合蛋白的制剂 |
| US20250197475A1 (en) * | 2022-03-18 | 2025-06-19 | Fab Biopharma, Inc. | Compositions and methods for treatment of sjögren's syndrome and/or systemic lupus erythematosus |
| CN120584137A (zh) | 2023-01-06 | 2025-09-02 | 阿帕特夫研究和发展有限公司 | 双特异性pd-l1和cd40结合分子以及其用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) * | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5714585A (en) * | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
| DK0695189T3 (da) * | 1992-12-29 | 1999-08-09 | Genentech Inc | Behandling af inflammatorisk tarmsygdom med IFN-gammainhibitorer |
| US20050147609A1 (en) * | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
| MXPA01007163A (es) * | 1999-01-15 | 2002-03-27 | Biogen Inc | Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos. |
| US7220840B2 (en) * | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
| EP1401870A4 (en) * | 2001-05-24 | 2006-04-19 | Human Genome Sciences | ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL) |
| US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| DE10148217C1 (de) * | 2001-09-28 | 2003-04-24 | Bosch Gmbh Robert | Verfahren, Computerprogramm und Steuer- und/oder Regelgerät zum Betreiben einer Brennkraftmaschine, sowie Brennkraftmaschine |
| JP2006500905A (ja) * | 2002-02-13 | 2006-01-12 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ヒト化ｇｍ−ｃｓｆ抗体 |
| WO2004011611A2 (en) * | 2002-07-25 | 2004-02-05 | Genentech, Inc. | Taci antibodies and uses thereof |
| TW200607523A (en) * | 2004-06-01 | 2006-03-01 | Domantis Ltd | Drug compositions, fusions and conjugates |
| EP1799246A4 (en) * | 2004-10-12 | 2009-08-12 | Amprotein Corp | CHIMERIC PROTEIN |
| AU2005313971B2 (en) * | 2004-12-08 | 2011-10-13 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
| US7939490B2 (en) * | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
| PT2343320T (pt) * | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| RU2447085C2 (ru) * | 2005-05-18 | 2012-04-10 | МорфоСис АГ | Анти-gm-csf антитела и их применение |
| WO2006130429A2 (en) * | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| NZ612578A (en) * | 2005-08-19 | 2014-11-28 | Abbvie Inc | Dual variable domain immunoglobin and uses thereof |
| US7846439B2 (en) * | 2006-02-01 | 2010-12-07 | Cephalon Australia Pty Ltd | Domain antibody construct |
| NZ573646A (en) * | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| MX2011000071A (es) * | 2008-07-02 | 2011-05-03 | Emergent Product Dev Seattle | Inmunoterapeuticos de interleucina-6 (il6). |
| NZ590667A (en) * | 2008-07-02 | 2013-01-25 | Emergent Product Dev Seattle | Tgf-b antagonist multi-target binding proteins |
| CA2732574A1 (en) * | 2008-07-28 | 2010-02-04 | Philip Tan | Multi-specific binding proteins targeting b cell disorders |
| NO2344540T3 (https=) * | 2008-10-02 | 2018-04-28 | ||
| AU2009303318B2 (en) * | 2008-10-10 | 2016-06-30 | Aptevo Research And Development Llc | TCR complex immunotherapeutics |
-
2009
- 2009-07-02 JP JP2011516886A patent/JP2011526792A/ja active Pending
- 2009-07-02 KR KR1020117002700A patent/KR20110044991A/ko not_active Withdrawn
- 2009-07-02 AU AU2009266863A patent/AU2009266863A1/en not_active Abandoned
- 2009-07-02 US US13/001,087 patent/US20110152173A1/en not_active Abandoned
- 2009-07-02 WO PCT/US2009/049603 patent/WO2010003108A2/en not_active Ceased
- 2009-07-02 CN CN2009801338489A patent/CN102171247A/zh active Pending
- 2009-07-02 CA CA2729749A patent/CA2729749A1/en not_active Abandoned
- 2009-07-02 NZ NZ590668A patent/NZ590668A/xx not_active IP Right Cessation
- 2009-07-02 MX MX2011000041A patent/MX2011000041A/es not_active Application Discontinuation
- 2009-07-02 BR BRPI0914005A patent/BRPI0914005A2/pt not_active IP Right Cessation
- 2009-07-02 EA EA201170028A patent/EA201170028A1/ru unknown
- 2009-07-02 EP EP09774557A patent/EP2310410A2/en not_active Withdrawn
-
2010
- 2010-12-26 IL IL210264A patent/IL210264A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526792A5 (https=) | ||
| JP6820242B2 (ja) | 抗体のＦｃ領域改変体 | |
| Silacci et al. | Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency | |
| JP2023525032A (ja) | Ｔ細胞阻害タンパク質を伴うおよび伴わない、ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 | |
| JP2015524799A5 (https=) | ||
| JP2020506898A5 (https=) | ||
| JP2011526794A5 (https=) | ||
| AU2020301529B2 (en) | TNFR2 agonists with improved stability | |
| JP2014518883A5 (https=) | ||
| RU2015142999A (ru) | Слитые белки, содержащие связывающие части pdgf и vegf, и способы их применения | |
| RU2749712C2 (ru) | IL-17A-связывающие полипептиды | |
| EP2721073A1 (en) | Soluble proteins for use as therapeutics | |
| PT2697257T (pt) | Proteínas de fusão fc compreendendo novos ligantes ou arranjos | |
| JP7097293B2 (ja) | ヒトＦｃ受容体に結合する融合タンパク質 | |
| CN102770537A (zh) | 用于纯化多肽多聚体的多肽的修饰方法 | |
| JP2022528324A (ja) | 抗ｉｌ１３ｒ抗体またはその結合フラグメントを用いた治療 | |
| WO2011079308A2 (en) | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof | |
| BR112020025030A2 (pt) | anticorpos que compreendem um polipeptídeo inserido na região de framework 3 | |
| WO2019096026A1 (zh) | 抗il-17抗体/tnfr ecd融合蛋白及其用途 | |
| RU2019123112A (ru) | Анти-il-5 антитела | |
| Richter et al. | Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity | |
| JP2014124186A (ja) | 多価抗体フラグメントおよびその三量体化複合体 | |
| CN106536567A (zh) | 新型多肽 | |
| AU2022381844A1 (en) | Novel proteins | |
| ITFI20090006A1 (it) | Processo per la produzione di proteine di fusione polivalenti e polispecifiche utilizzando come struttura portante l'uteroglobina e prodotti cosi' ottenuti. |